ADMA Biologics (NASDAQ:ADMA) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Valuation and Earnings
This table compares ADMA Biologics and Gamida Cell’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ADMA Biologics||$29.35 million||8.68||-$48.28 million||($0.92)||-3.21|
|Gamida Cell||N/A||N/A||-$34.35 million||($1.69)||-2.64|
Gamida Cell has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ADMA Biologics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
This table compares ADMA Biologics and Gamida Cell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for ADMA Biologics and Gamida Cell, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ADMA Biologics presently has a consensus target price of $7.50, suggesting a potential upside of 154.24%. Gamida Cell has a consensus target price of $16.33, suggesting a potential upside of 266.22%. Given Gamida Cell’s stronger consensus rating and higher possible upside, analysts clearly believe Gamida Cell is more favorable than ADMA Biologics.
Insider & Institutional Ownership
56.1% of ADMA Biologics shares are owned by institutional investors. Comparatively, 21.8% of Gamida Cell shares are owned by institutional investors. 11.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Gamida Cell beats ADMA Biologics on 7 of the 13 factors compared between the two stocks.
ADMA Biologics Company Profile
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Gamida Cell Company Profile
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.